Misonix (NASDAQ:MSON) Earns Buy Rating from Canaccord Genuity
Canaccord Genuity reiterated their buy rating on shares of Misonix (NASDAQ:MSON) in a report published on Thursday morning, The Fly reports. They currently have a $30.00 price objective on the medical equipment provider’s stock, up from their prior price objective of $24.00.
MSON has been the topic of a number of other reports. TheStreet downgraded shares of Misonix from a c- rating to a d rating in a research note on Thursday, June 20th. BidaskClub raised shares of Misonix from a buy rating to a strong-buy rating in a research note on Wednesday, July 3rd. ValuEngine downgraded shares of Misonix from a buy rating to a hold rating in a research note on Thursday, August 1st. Finally, BTIG Research started coverage on shares of Misonix in a research note on Wednesday, June 12th. They set a buy rating and a $29.00 target price on the stock. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of Buy and an average price target of $28.33.
Misonix stock opened at $20.82 on Thursday. The company’s 50 day simple moving average is $23.77 and its 200-day simple moving average is $21.09. Misonix has a 1 year low of $13.19 and a 1 year high of $27.54.
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Recommended Story: What is an inverted yield curve?
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.